RxDoctor Payments Data

Misael Marquez, MD

Internal Medicine · Coos Bay, ORNPI 1922088426

Payments from drug & device makers

$159in general payments, 2019–2025

Across 9 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$50
  • Otsuka America Pharmaceutical, Inc.$42
  • Sunovion Pharmaceuticals Inc.$29
  • Novo Nordisk$21
  • Linus Health, Inc.$17

What the payments were for

  • Food & beverage$10969%
  • Education$5031%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$50
Otsuka America Pharmaceutical, Inc.2$42
Sunovion Pharmaceuticals Inc.3$29
Novo Nordisk1$21
Linus Health, Inc.1$17

How this compares

$159 in reported general payments places this provider in the 75th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$205,855
Medicare patients
654
Services billed
5,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban233$162,978
JardianceEmpagliflozin155$98,335
OzempicSemaglutide38$53,936
JanuviaSitagliptin Phosphate91$39,126
TrulicityDulaglutide18$34,931
FarxigaDapagliflozin Propanediol31$33,917
MounjaroTirzepatide34$33,859
XareltoRivaroxaban28$32,855
TradjentaLinagliptin84$32,618
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$29,802
Breo ElliptaFluticasone/Vilanterol45$21,542
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$11,546
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$10,406
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$8,219
Atorvastatin Calcium605$7,941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21$53,93638 claims
AstraZenecaFarxiga$50$33,91731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,363 internal medicine providers in Oregon.

Other internal medicine in Coos Bay

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →